Credit Suisse’s Alethia Young maintains an Outperform rating on the company with a price target of $165.
Young believes that “so far that the company has not uncovered anything yet that would require restatement or suggest wrongdoing, but the company is taking the matter raised very seriously.”
The analyst explained it was still early in the investigation, making it difficult to predict the final outcome, while Alexion Pharma has been “relatively quiet” about the ongoing investigation.
“As it relates to timing, the company thinks that it will take longer than a matter of days to file the 10Q and we would guess it could take weeks,” Young stated.
Alexion Pharma also indicated that the investigation was distinct and separate from the SEC and DoJ FCPA information requests from 2015.
The allegation regarding the
|Nov 2016||Deutsche Bank||Initiates Coverage On||Buy|
|Oct 2016||FBR Capital||Upgrades||Underperform||Market Perform|
|Oct 2016||Brean Capital||Assumes||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.